Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention

Precision medicine is a medical model that proposes the customization of medical treatments to the individual patient, as opposed to a one-drug-fits-all model. Such a personalized medicine approach has been widely adopted in several medical fields, such as cancer medicine, but the implementation of precision medicine in cardiovascular medicine has not been similarly straightforward. Because pharmacogenomics plays an important role in the safety and efficacy of cardiovascular drug therapy, there has been a great interest in the use of tools aiming at personalizing antiplatelet therapy. Moreover, antiplatelet therapy is essential for the treatment of cardiovascular patients to reduce the risk of thrombotic complications, particularly those undergoing percutaneous coronary intervention, but it is inevitably associated with increased bleeding risk. In this review, the authors discuss the rationale, summarize the evidence and discuss the current and future directions for the personalization of antiplatelet treatment regimens in patients undergoing percutaneous coronary intervention.

Automated summary

Precision medicine proposes customized treatments for individual patients instead of a one-size-fits-all model. While widely adopted in cancer medicine, implementing precision medicine in cardiovascular medicine is more challenging. Personalized antiplatelet therapy is crucial for cardiovascular patients, but it is associated with bleeding risks. This review discusses the rationale, evidence, and future directions in personalizing antiplatelet treatment for patients undergoing percutaneous coronary intervention.